NCT04021966 (CO2VVA) is a NA clinical trial of Vaginal laser application in Vulvovaginal Atrophy, sponsored by prof. dr. Jan Deprest.

Who is sponsoring NCT04021966?

NCT04021966 is sponsored by prof. dr. Jan Deprest.

What drugs are being tested in NCT04021966?

Interventions in NCT04021966: Vaginal laser application.

What condition does NCT04021966 study?

NCT04021966 studies Vulvovaginal Atrophy.

Is NCT04021966 still recruiting?

NCT04021966 is currently completed. Last updated 10 January 2022.

Last reviewed 2022-01-10 · How we verify

NCT04021966: CO2VVA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Fractional CO2 Laser for the Treatment of Vulvovaginal Atrophy: a Double-blinded Randomized Placebo-controlled Clinical Trial.

Completed NA Last updated 10 January 2022

What this trial tests

NA trial testing Vaginal laser application in Vulvovaginal Atrophy in 60 participants. Completed in 31 December 2021.

Timeline

1 August 2019

Primary endpoint
27 September 2021

31 December 2021

Quick facts

Lead sponsor	prof. dr. Jan Deprest
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	1 August 2019
Primary completion	27 September 2021
Estimated completion	31 December 2021
Sites	1 location across Belgium

Drugs / interventions tested

Vaginal laser application

Conditions studied

Vulvovaginal Atrophy — all drugs for Vulvovaginal Atrophy →

Sponsor

prof. dr. Jan Deprest

Who can join

Eligibility, female only, with Vulvovaginal Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose of the trial is to study the efficacy of fractional laser in alleviating genitourinary symptoms in menopausal women. Primary outcome of the study is the efficacy of the laser procedure, intended as the amelioration of the severity of most bothersome symptom (MBS). Therefore we conducted a single center, double-blinded randomized placebo-controlled cross-over trial.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Energy-based interventions for genitourinary syndrome of menopause: a systematic review of randomized controlled trials and prospective observational studies.
Zerzan NL, Greer N, Ullman KE, Sowerby C, et al · · 2025 · cited 2× · PMID 39774067 · DOI 10.1097/gme.0000000000002465

Verify or expand the search:

Other recruiting trials for Vulvovaginal Atrophy

Currently open trials in the same condition.

NCT05562518 — GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therap · Phase 4 · active not recruiting

Other prof. dr. Jan Deprest trials

Trials by the same sponsor.

NCT05037383 — Motion and Viewing Analysis of Surgeons During Minimally Invasive Gynecological Interventions · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04021966 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by prof. dr. Jan Deprest
Last refreshed: 10 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04021966.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing